Recombinant heat shock protein 65 carrying hepatitis B core antigen induces HBcAg-specific CTL response

Vaccine

Volumn 25, Issue 22, 2007, Pages 4478-4486

  Yang, Bing fen ^a   Zhao, Hong liang ^a   Xue, Chong ^a   Xiong, Xiang hua ^a   Zhang, Wei ^a   Yao, Xue qin ^a   Liu, Zhi min ^a  

^a BEIJING INSTITUTE OF BIOTECHNOLOGY   (China)

Author keywords

Chronic hepatitis B virus infection; Core antigen of hepatitis B virus (HBcAg); Heat shock protein 65; Therapeutic vaccine

Indexed keywords

CHIMERIC PROTEIN; EPITOPE; HEAT SHOCK PROTEIN 65; HEPATITIS B CORE ANTIGEN; HEPATITIS B VACCINE; HSP65BC PROTEIN; HYBRID PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGENICITY; ARTICLE; CARBOXY TERMINAL SEQUENCE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; GENE SEQUENCE; HEPATITIS B; HEPATITIS B VIRUS; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; MOUSE; MOUSE STRAIN; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL;

ANIMALS; ANTIGEN PRESENTATION; BACTERIAL PROTEINS; CHAPERONINS; ESCHERICHIA COLI; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B CORE ANTIGENS; HEPATITIS B VACCINES; HEPATITIS B, CHRONIC; HUMANS; MICE; MICE, INBRED BALB C; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 34247610883     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.03.020     Document Type: Article

References (55)

1. Lee W.M. Hepatitis B virus infection. N Engl J Med 337 (1997) 1733-1745
2. Wright T.L., and Lau J.Y. Clinical aspects of hepatitis B virus infection. Lancet 342 (1993) 1340-1344
3. Pol S. Natural history of hepatitis B infection. Presse Med 35 (2006) 308-316
4. Chisari F.V. Hepatitis B virus immunopathogenesis. Annu Rev Immunol 13 (1995) 29-60
5. Bertoletti A., D'Elios M.M., Ferrari C., De Carli M., Zignego A.L., Durazzo M., et al. Different cytokine profiles of intraphepatic T cells in chronic hepatitis B and hepatitis C virus infections. Gastroenterology 112 (1997) 193-199
6. Jung M.C., Hartmann B., Pape G.R., Diepolder H., Gruber R., Schraut W., et al. Virus-specific lymphokine production differs quantitatively but not qualitatively in acute and chronic hepatitis B infection. Virology 261 (1999) 165-172
7. Penna A., Del Prete G., Cavalli A., Bertoletti A., D'Elios M.M., Ferrari C., et al. Predominant T-helper 1 cytokine profile of hepatitis B virus nucleocapsid-specific T cells in acute self-limited hepatitis B. Hepatology 25 (1997) 1022-1027
8. Tiné F., Liberati A., Craxi A., Almasio P., and Pagliaro L. Interferon treatment in patients with chronic hepatitis B: a meta-analysis of the published literature. J Hepatol 18 (1993) 154-162
9. Wong D.K., Cheung A.M., O'Rourke K., Naylor C.D., Detsky A.S., and Heathcote J. Effect of alpha-interferon in patients with hepatitis B e antigen-positive chronic hepatitis B: a meta-analysis. Ann Intern Med 119 (1993) 312-323
10. Niederau C., Heintges T., Lange S., Goldmann G., Niederau C.M., Mohr L., et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 334 (1996) 1422-1427
11. Korenman J., Baker B., Waggoner J., Everhart J.E., Di Bisceglie A.M., and Hoofnagle J.H. Long-term remission of chronic hepatitis B after alpha-interferon therapy. Ann Intern Med 114 (1991) 629-634
12. Terrsi J., Earnest-Sliveira L., Deliyannis G., Edgtton K., Zhuang H., Locarnini S.A., et al. Reduced antigenicity of the hepatitis B virus HBsAg protein arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamifudine therapy. Virology 293 (2002) 305-313
13. Benhamou Y., Dohin E., Lunel-Fabiani F., Poynard T., Huraux J.M., Katlama C., et al. Efficacy of lamivudine on replication of hepatitis B virus in HIV-infected patients. Lancet 345 (1995) 396-397
14. Dienstag J.L., Perrillo R.P., Schiff E.R., Bartholomew M., Vicary C., and Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 333 (1995) 1657-1661
15. Lai C.L., Chien R.N., Leung N.W., Chang T.T., Guan R., Gray D.F., and Asia Hepatitis Lamivudine Study Group. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 339 (1998) 61-68
16. Kazim S.N., Sarin S.K., Sharma B.C., Khan L.A., and HasNain S.E. Characterization of naturally occurring and Lamivudine-induced surface gene mutants of hepatitis B virus in patients with chronic hepatitis B in India. Inter virology 49 (2006) 152-160
17. Bocher W.O., Dekel B., Schwerin W., Geissler M., Hoffmann S., and Rohwer A. Induction of strong hepatitis B virus (HBV) specific T helper cell and cytotoxic T lymphocyte responses by therapeutic vaccination in the trimera mouse model of chronic HBV infection. Eur J Immunol 31 (2001) 2071
18. Ni Y., Ma K., Ni J., Zheng X., Wang Y., and Xiong S. A rapid and simple approach to preparation of monoclonal antibody based on DNA immunization. Cell Mol Immunol 4 (2004) 295-299
19. Wen Y.M., Wu X.H., Hu D.C., Zhang Q.P., and Guo S.Q. Hepatitis B vaccine and anti-HBs comples as approach for vaccine therapy. Lancet 345 (1995) 1575
20. Dikici B., Bosnak M., Ucmak H., Dagli A., Ece A., and Haspolat K. Failure of therapeutic vaccination using hepatitis B surface antigen vaccine in the immunotolerant phase of children with chronic hepatitis B infection. J Gastroenterol Hepatol 18 (2003) 218-222
21. Wu Y., Zhang J., Chen S., Chen A., Wang L., and Li J. Frequencies of epitope-specific cytotoxic T lymphocytes in active chronic viral hepatitis B infection by using MHC class I peptide tetramers. Immunol Lett 92 (2004) 253-258
22. Srivastava P.K., Menoret A., Basu S., Binder R.J., and McQuade K.L. Heat shock proteins come of age: primitive functions acquire new roles in an adaptive world. Immunity 8 (1998) 657-665
23. Srivastava P. Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses. Annu Rev Immunol 20 (2002) 395-425
24. Peng M., Chen M., Ling N., Xu H., Qing Y., and Ren H. Novel vaccines for the treatment of chronic HBV infection based on mycobacterial heat shock protein 70. Vaccine 24 (2006) 887-896
25. Li X., Yang X., Li L., Liu H., and Liu J. A truncated C-terminal fragment of Mycobacterium tuberculosis HSP70 gene enhanced potency of HBV DNA vaccine. Vaccine 24 (2006) 3321-3331
26. Nicchitta C.V. Biochemical, cell biological and immunological issues surrounding the endoplasmic reticulum chaperone GRP94/gp96. Curr Opin Immunol 10 (1998) 103-109
27. Tamura Y., Peng P., Liu K., Daou M., and Srivastava P.K. Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science 278 (1997) 117-119
28. Multhoff G., Botzler C., Jennen L., Schmidt J., Ellwart J., and Issels R. Heat shock protein 72 on tumor cells a recognition structure for natural killer cells. J Immunol 158 (1997) 4341-4350
29. Basu S., Binder R.J., Suto R., Anderson K.M., and Srivastava P.K. Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-kB pathway. Int Immunol 12 (2000) 1539-1546
30. Suto R., and Srivastava P.K. A mechanism for the special immunogenicity of heat shock protein-chaperoned peptides. Science 269 (1995) 1585-1588
31. Wells A.D., Rai S.K., Salvato M.S., Band H., and Malkovsky M. Hsp 72-mediated augmentation of MHC class I surface expression and endogeneous antigen presentation. Int Immunol 10 (1998) 609-617
32. Ciupitu A.M., Petersson M., O'Donnell C.L., Williams K., Jindal S., Kiessling R., et al. Immunization with a lymphocytic choriomeningitis virus peptide mixed with heat shock protein 70 results in protective antiviral immunity special cytotoxic T lymphocytes. J Exp Med 187 (1998) 685-691
33. Arnold D., Faath S., Rammensee H., and Shild H. Cross-priming of minor histocompatibility antigen-special cytotoxic T cells upon immunization with the heat shock protein gp96. J Exp Med 182 (1995) 885-889
34. Singh-Jasuja H., Scherer H.U., Hilf N., Arnold-Schild D., Rammensee H.G., Toes R.E., et al. The heat shock protein gp96 induces maturation of dendritic cells and down-regulation of its receptor. Eur J Immunol 30 (2000) 2211-2215
35. Binder R.J., Anderson K.M., Basu S., and Srivastava P.K. Cutting edge: heat shock protein gp96 induces maturation and migration of CD11c t cells in vivo. J Immunol 165 (2000) 6029-6035
36. Tamura Y., Peng P., Liu K., Daou M., and Srivastava P.K. Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science 278 (1997) 117-120
37. Chen K., Lu J.H., Wang L., and Gan Y.H. Mycobacterial heat shock protein 65 enhance antigen cross-presentation in dendritic cells independent of Toll-like receptor 4 signaling. J Leukoc Biol 75 (2004) 260-266
38. Milich D.R., McLachlan A., Moriarty A., and Thornton G.B. Immune response to hepatitis B virus core antigen (HBcAg): localization of T cell recognition sites within HBcAg/HBeAg. J Immunol 139 (1987) 1223-1231
39. Milich D.R., and McLachlan A. The nucleocapsid of hepatitis B virus is both a T-cell-independent and a T-cell-dependent antigen. Science 234 (1986) 1398-1401
40. Milich D.R., McLachlan A., Thornton G.B., and Hughes J.L. Antibody production to the nucleocapsid snd envelope of the hepatitis B vius primed by a single synthetic T cell site. Nature 329 (1987) 547-549
41. Bertoletti A., Chisari F.V., Penna A., Guilhot S., Galati L., Missale G., et al. Definition of a minimal optimal cytotoxic T-cell epitope within the hepatitis B virus nucleocapsid protein. J Virol 67 (1993) 2376-2380
42. Bertoletti A., Southwood S., Chesnut R., Sette A., Falco M., Ferrara G.B., et al. Molecular features of the hepatitis B virus nucleocapsid T-cell epitope 18-27: interaction with HLA and T-cell receptor. Hepatology 26 (1997) 1027-1034
43. Stemmer W.P., Crameri A., Ha K.D., Brennan T.M., and Heyneker H.L. Single-step assembly of a gene and entire plasmid from large numbers of oligodeoxyribonucleotides. Gene 164 (1995) 49-53
44. 2+-chelate affinity chromatography. J Virol Methods 77 (1999) 189-197
45. Zihai Li. In vitro reconstitution of heat shock protein-peptide complexes for generating peptide-specific vaccines against cancers and infectious diseases. Methods 32 (2004) 25-28
46. Goldstone S.E., Palefsky J.M., Winnett M.T., and Neefe J.R. Activity of HspE7, a novel immunotherapy, in patients with anogenital warts. Dis Colon Rectum 45 (2002) 502-507
47. Peng L., Wang B., and Ren P. Reducton of MTT by flavonoids in the absence of cells. Colloids Surf B: Biointerfaces 45 (2005) 108-111
48. Sturm A., Baumgart D.C., d'Heureuse J.H., Hotz A., Wiedenmann B., and Dignass A.U. CXCL8 modulates human intestinal epithelial cells through a CXCR1 dependent pathway. Cytokine 29 (2005) 42-48
49. Guo G., Chen S., Zhang J., Luo L., Yu J., Dong H., et al. Antitumor activity of a fusion of esophageal carcinoma cells with dendritic cells derived from cord blood. Vaccine 23 (2005) 5225-5230
50. Kakimi K., Isogawa M., Chung J., Sette A., and Chisari F.V. Immunogenicity and tolerogenicity of hepatitis B virus structural and nonstructural proteins: implications for immunotherapy of persistent viral infections. J Virol 76 (2002) 8609-8620
51. Engler O.B., Dai W.J., Sette A., Hunziker I.P., Reichen J., Pichler W.J., et al. Peptide vaccines against hepatitis B virus: from animal model to human studies. Mol Immunol 38 (2001) 457-465
52. Sette A.D., Oseroff C., Sidney J., Alexander J., Chesnut R.W., Kakimi K., et al. Overcoming T cell tolerance to the hepatitis B virus surface antigen in hepatitis B virus-transgenic mice. J Immunol 166 (2001) 1389-1397
53. Anthony L.S., Wu H., Sweet H., Turnnir C., Boux L.J., and Mizzen L.A. Priming of CD8 + CTL effector cells in mice by immunization with a stress protein-influenza virus nucleoprotein fusionmolecule. Vaccine 17 (1999) 378-383
54. Chu N.R., Wu H.B., Wu T.C., Boux L.J., Mizzen L.A., and Siegel M.I. Immunotherapy of a human papillomavirus type 16 E7-expressing tumor by administration of fusion protein comprised of Mycobacterium bovis BCG Hsp65 and HPV16 E7. Cell Stress Chaperones 5 (2000) 401-405
55. Chu N.R., Wu H.B., Wu T., Boux L.J., Siegel M.I., and Mizzen L.A. Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guerin (BCG) Hsp65 and HPV16 E7. Clin Exp Immunol 121 (2000) 16-25